Adalimumab biosimilar (Mabscale)

N/A

Report date: 2024/01/25 20:04:27

Base Information

Drug NameAdalimumab biosimilar (Mabscale)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesMabscale LLC
China Registration ClassN/A

Develop Information

Active CompaniesMabscale LLC
Inactive CompaniesN/A
Active IndicationsPlaque psoriasis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A